MGMT and astrocytoma (excluding glioblastoma): Furthermore, Mann-Whitney and Kruskal-Wallis tests revealed significant multi-biomarker risk-score associations with astrocytoma pathological grade (p < 0.001), patient disease appearance age (≤ 50 and >50 years, p < 0.001), IDH status (wild-type and mutation, p < 0.001), and MGMT status (methylated and unmethylated, p = 0.027), but not gender (p = 0.067) (Table 1).